查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933285

全球GLP-1受體激動劑市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

GLP-1 Receptor Agonist Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

GLP-1受體激動劑市場成長因子

受全球第2型糖尿病和肥胖症負擔日益加重的推動，全球GLP-1受體激動劑市場正成為製藥業成長最快的細分市場之一。 GLP-1受體激動劑是一類模擬天然存在的升糖素樣勝肽-1激素作用的藥物，有助於調節血糖、促進胰島素分泌、抑制食慾和促進體重減輕。根據 Fortune Business Insights 預測，全球 GLP-1 受體激動劑市場規模預計在 2025 年達到 628.3 億美元，並在 2026 年成長至 733.9 億美元。預計到 2034 年，該市場規模將達到 2,541.9 億美元，2026 年至 2034 年的複合年增長率 (CAGR) 高達 16.80%。北美地區在 2025 年將佔市場主導地位，市場佔有率達到 55.51%，這主要得益於該地區高昂的醫療保健支出和龐大的患者群體。 市場動態 市場驅動因素 2 型糖尿病和肥胖症盛行率的不斷上升是 GLP-1 受體激動劑市場的主要驅動因素。根據國際糖尿病聯盟 (IDF) 發布的 "糖尿病地圖集" (2021)，2 型糖尿病影響著全球約 10.5% 的成年人口。世界衛生組織 (WHO) 的報告指出，自 1990 年以來，肥胖症的盛行率增加了一倍以上。 GLP-1 受體激動劑具有改善血糖控制和輔助減肥的雙重功效，因此在治療這兩種疾病方面都非常有效。它們作為第一線或輔助療法的應用日益廣泛，尤其是在心血管風險患者中，這顯著推動了市場需求。

市場限制因子

儘管需求強勁，但 GLP-1 受體激動劑的高昂價格仍然是一個主要限制因素。在美國，每月治療費用可能接近 1000 美元，這限制了許多患者的用藥。缺乏仿製藥和複雜的生產流程也加劇了定價方面的挑戰，並可能阻礙其廣泛應用，尤其是在對成本敏感的地區。

市場機會

發展中國家為GLP-1受體激動劑生產商提供了巨大的未開發成長機會。未確診糖尿病的高發生率、先進療法的可近性有限以及不斷完善的醫療基礎設施，都創造了長期成長潛力。在這些地區推出價格合理的製劑並加強分銷網絡，可以顯著擴大市場規模。

市場挑戰

市場面臨的主要挑戰之一是GLP-1受體激動劑的短缺，這是由於全球對肥胖症和糖尿病治療的需求激增所致。然而，製藥公司正積極投資擴大產能，以應對供應限制。

市場趨勢

影響市場的顯著趨勢之一是人工智慧（AI）與數位健康解決方案的融合。人工智慧驅動的工具正越來越多地被用於個人化治療方案的選擇、預測患者的反應以及改善治療效果。此外，口服 GLP-1 製劑的研發勢頭強勁，與注射劑相比，口服製劑使用更方便，患者依從性也更高。

市場區隔分析

依藥物類型劃分，索瑪魯肽憑藉其在血糖控制和體重減輕方面的卓越療效、獲批多種適應症以及注射劑和口服劑型，佔市場主導地位。其他藥物，如艾塞那肽、利拉魯肽、度拉魯肽以及新興的聯合療法，也正在推動市場擴張。

依年齡組劃分，成人市場佔最大佔有率，這主要歸因於第 2 型糖尿病和肥胖症的高發生率。然而，由於針對兒童患者的臨床試驗和監管批准的增加，預計兒童市場將以更快的速度成長。

依給藥途徑劃分，注射用 GLP-1 療法的廣泛應用主導了腸外給藥市場。然而，由於患者越來越傾向於非注射治療，口服藥物市場預計將快速成長。

依適應症劃分，糖尿病仍然是主要市場，但由於核准藥物的增加及其卓越的體重管理效果，肥胖症市場預計將在預測期內實現最高的複合年增長率。

區域洞察

北美預計將保持領先地位，在強勁的研發投入和高疾病盛行率的支撐下，2025年市場規模將達到348.8億美元，2026年將達到407.4億美元。歐洲由於眾多大型製藥公司的存在，佔第二大市場。同時，由於肥胖率上升和醫療保健服務可近性的提高，亞太地區預計將經歷快速成長。由於意識和基礎設施的持續改善，拉丁美洲和中東及非洲地區具有長期成長潛力。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區主要適應症的流行情況（2025 年）
  • 主要公司產品線分析
  • 主要公司新產品發布
  • 主要產業趨勢：併購、業務合作等等。
  • COVID-19 對市場的影響

第五章 全球 GLP-1 受體激動劑市場分析：洞察與預測 (2021-2034)

  • 市場分析、洞察與預測：依藥物類型劃分
    • 索瑪魯肽
    • 艾塞那肽
    • 利西拉肽
    • 利拉魯肽
    • 度拉魯肽
    • 其他
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測：依年齡組別劃分
    • 兒童
    • 成人
  • 市場分析、洞察與預測：依適應症
    • 糖尿病
    • 肥胖症
    • 其他
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美 GLP-1 受體激動劑市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲 GLP-1受體激動劑市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區 GLP-1 受體激動劑市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲 GLP-1 受體激動劑市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲 GLP-1 受體激動劑市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第11章 競爭分析

  • 全球市場佔有率分析(2025年)
  • 企業簡介
    • Eli Lilly and Company
    • Sanofi
    • Novo Nordisk A/S
    • AstraZeneca
    • Pfizer, Inc.
    • Glenmark Pharmaceuticals Limited
    • Teva Pharmaceutical Industries Ltd.
Product Code: FBI112827

Growth Factors of GLP-1 receptor agonist Market

The global GLP-1 receptor agonist market has emerged as one of the fastest-growing segments within the pharmaceutical industry, driven by the rising burden of type 2 diabetes and obesity worldwide. GLP-1 receptor agonists are a class of drugs that mimic the action of the naturally occurring glucagon-like peptide-1 hormone, helping regulate blood glucose levels, stimulate insulin secretion, suppress appetite, and promote weight loss. According to Fortune Business Insights, the global GLP-1 receptor agonist market was valued at USD 62.83 billion in 2025, is projected to grow to USD 73.39 billion in 2026, and is expected to reach USD 254.19 billion by 2034, registering a strong CAGR of 16.80% during 2026-2034. North America dominated the market with a 55.51% share in 2025, supported by high healthcare spending and a large patient population.

Market Dynamics

Market Drivers

The increasing prevalence of type 2 diabetes and obesity is the primary driver of the GLP-1 receptor agonist market. As per the IDF Diabetes Atlas (2021), type 2 diabetes affects around 10.5% of the global adult population, while WHO reports indicate that obesity has more than doubled since 1990. GLP-1 receptor agonists offer dual benefits by improving glycemic control and supporting weight reduction, making them highly effective for managing both conditions. Their growing use as first-line or add-on therapies, particularly in patients with cardiovascular risk, is significantly boosting market demand.

Market Restraints

Despite strong demand, the high cost of GLP-1 receptor agonists remains a major restraint. In the U.S., monthly treatment costs can reach nearly USD 1,000, limiting accessibility for many patients. The lack of generic alternatives and complex manufacturing processes further contribute to pricing challenges, which may restrict broader adoption, especially in cost-sensitive regions.

Market Opportunities

Developing countries present significant unmet opportunities for GLP-1 receptor agonist manufacturers. High rates of undiagnosed diabetes, limited access to advanced therapies, and expanding healthcare infrastructure create long-term growth potential. Introducing affordable formulations and strengthening distribution networks in these regions could substantially expand the market footprint.

Market Challenges

A key challenge faced by the market is the shortage of GLP-1 receptor agonist drugs, driven by overwhelming global demand for obesity and diabetes treatment. However, pharmaceutical companies are actively investing in manufacturing capacity expansion to address supply constraints.

Market Trends

One of the prominent trends shaping the market is the integration of artificial intelligence (AI) and digital health solutions. AI-driven tools are increasingly being used to personalize treatment selection, predict patient response, and improve therapy outcomes. Additionally, the development of oral GLP-1 formulations is gaining momentum, offering improved convenience and patient compliance compared to injectable options.

Segmentation Analysis

By drug type, semaglutide dominates the market due to its superior efficacy in glycemic control and weight loss, approval for multiple indications, and availability in both injectable and oral forms. Other drugs such as exenatide, liraglutide, dulaglutide, and emerging combination therapies also contribute to market expansion.

By age group, the adult segment holds the largest share owing to the high prevalence of type 2 diabetes and obesity. However, the pediatric segment is expected to grow at a faster rate due to increasing clinical trials and regulatory approvals for younger populations.

By route of administration, the parenteral segment dominates due to the widespread use of injectable GLP-1 therapies, while the oral segment is expected to grow rapidly with rising patient preference for non-injectable treatments.

By indication, diabetes remains the dominant segment, while the obesity segment is projected to grow at the highest CAGR during the forecast period due to increasing approvals and strong weight-management outcomes.

Regional Insights

North America led the market with a valuation of USD 34.88 billion in 2025 and USD 40.74 billion in 2026, driven by strong R&D investments and high disease prevalence. Europe holds the second-largest share due to the presence of major pharmaceutical players, while Asia Pacific is expected to witness rapid growth supported by rising obesity rates and improving healthcare access. Latin America and the Middle East & Africa offer long-term growth potential as awareness and infrastructure continue to improve.

Competitive Landscape

The market is highly consolidated, with Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca, and Sanofi holding significant shares. Strong product portfolios, regulatory approvals, strategic collaborations, and manufacturing expansions are key strategies adopted by these players to maintain their competitive positions.

Conclusion

The global GLP-1 receptor agonist market is set for exceptional growth, expanding from USD 62.83 billion in 2025 to USD 254.19 billion by 2034. Rising diabetes and obesity prevalence, expanding therapeutic applications, and continuous innovation in drug formulations are driving market momentum. While high costs and supply challenges remain, increasing investments, technological integration, and expanding access in emerging markets are expected to sustain strong long-term growth for the GLP-1 receptor agonist market.

Segmentation By Drug

  • Semaglutide
  • Exenatide
  • Lixisenatide
  • Liraglutide
  • Dulaglutide
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Age Group

  • Pediatric
  • Adults

By Indication

  • Diabetes
  • Obesity
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug, By Route of Administration, By Age Group, By Indication, By Distribution Channel, and By Country/ Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Indications, By Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. New Product Launches, by Key Players
  • 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.5. Impact of COVID-19 on the Market

5. Global GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug
    • 5.1.1. Semaglutide
    • 5.1.2. Exenatide
    • 5.1.3. Lixisenatide
    • 5.1.4. Liraglutide
    • 5.1.5. Dulaglutide
    • 5.1.6. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Age Group
    • 5.3.1. Pediatric
    • 5.3.2. Adults
  • 5.4. Market Analysis, Insights and Forecast - By Indication
    • 5.4.1. Diabetes
    • 5.4.2. Obesity
    • 5.4.3. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
  • 5.6. Market Analysis, Insights and Forecast - Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug
    • 6.1.1. Semaglutide
    • 6.1.2. Exenatide
    • 6.1.3. Lixisenatide
    • 6.1.4. Liraglutide
    • 6.1.5. Dulaglutide
    • 6.1.6. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Age Group
    • 6.3.1. Pediatric
    • 6.3.2. Adults
  • 6.4. Market Analysis, Insights and Forecast - By Indication
    • 6.4.1. Diabetes
    • 6.4.2. Obesity
    • 6.4.3. Others
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug
    • 7.1.1. Semaglutide
    • 7.1.2. Exenatide
    • 7.1.3. Lixisenatide
    • 7.1.4. Liraglutide
    • 7.1.5. Dulaglutide
    • 7.1.6. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Age Group
    • 7.3.1. Pediatric
    • 7.3.2. Adults
  • 7.4. Market Analysis, Insights and Forecast - By Indication
    • 7.4.1. Diabetes
    • 7.4.2. Obesity
    • 7.4.3. Others
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.6.1. Germany
    • 7.6.2. U.K.
    • 7.6.3. France
    • 7.6.4. Italy
    • 7.6.5. Spain
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug
    • 8.1.1. Semaglutide
    • 8.1.2. Exenatide
    • 8.1.3. Lixisenatide
    • 8.1.4. Liraglutide
    • 8.1.5. Dulaglutide
    • 8.1.6. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Age Group
    • 8.3.1. Pediatric
    • 8.3.2. Adults
  • 8.4. Market Analysis, Insights and Forecast - By Indication
    • 8.4.1. Diabetes
    • 8.4.2. Obesity
    • 8.4.3. Others
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug
    • 9.1.1. Semaglutide
    • 9.1.2. Exenatide
    • 9.1.3. Lixisenatide
    • 9.1.4. Liraglutide
    • 9.1.5. Dulaglutide
    • 9.1.6. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Age Group
    • 9.3.1. Pediatric
    • 9.3.2. Adults
  • 9.4. Market Analysis, Insights and Forecast - By Indication
    • 9.4.1. Diabetes
    • 9.4.2. Obesity
    • 9.4.3. Others
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies
    • 9.5.3. Online Pharmacies
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa GLP-1 Receptor Agonists Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug
    • 10.1.1. Semaglutide
    • 10.1.2. Exenatide
    • 10.1.3. Lixisenatide
    • 10.1.4. Liraglutide
    • 10.1.5. Dulaglutide
    • 10.1.6. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Age Group
    • 10.3.1. Pediatric
    • 10.3.2. Adults
  • 10.4. Market Analysis, Insights and Forecast - By Indication
    • 10.4.1. Diabetes
    • 10.4.2. Obesity
    • 10.4.3. Others
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Eli Lilly and Company
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Novo Nordisk A/S
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AstraZeneca
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Pfizer, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Glenmark Pharmaceuticals Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Teva Pharmaceutical Industries Ltd.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 2: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 4: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 5: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 8: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 10: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 11: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 14: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 16: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 17: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 20: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 21: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 22: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 23: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 26: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 28: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 29: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Drug, 2021-2034
  • Table 32: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 33: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Age Group 2021-2034
  • Table 34: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 35: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa GLP-1 Receptor Agonists Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global GLP-1 Receptor Agonists Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025 & 2034
  • Figure 3: Global GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025 & 2034
  • Figure 6: Global GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global GLP-1 Receptor Agonists Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 9: North America GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 10: North America GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 11: North America GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 12: North America GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 13: North America GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 14: North America GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 15: North America GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 16: North America GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America GLP-1 Receptor Agonists Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America GLP-1 Receptor Agonists Market Value Share (%), By Country, 2025
  • Figure 20: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 21: Europe GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 22: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 23: Europe GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 24: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 25: Europe GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 26: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 27: Europe GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 28: Europe GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 33: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 34: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 35: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 36: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion),by Age Group, 2025 & 2034
  • Figure 37: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 38: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 39: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 40: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 45: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 46: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 47: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 48: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 49: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 50: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 51: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 52: Latin America GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Drug, 2025 & 2034
  • Figure 57: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Drug, 2025
  • Figure 58: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 59: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Route of Administration, 2025
  • Figure 60: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 61: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Age Group, 2025
  • Figure 62: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 63: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Indication, 2025
  • Figure 64: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa GLP-1 Receptor Agonists Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa GLP-1 Receptor Agonists Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global GLP-1 Receptor Agonists Market Share (%), By Company, 2025